<DOC>
	<DOC>NCT01265797</DOC>
	<brief_summary>Cranial electrotherapy stimulation (CES) may be a safe adjunct to medical treatment for pain relief in migraine patients. However, despite the number of CES studies done, many have been open label, single blinded, or have utilized a small group of patients.</brief_summary>
	<brief_title>Cranial Electrotherapy Stimulation in the Treatment of Migraine Headaches</brief_title>
	<detailed_description>This study will evaluate the efficacy of the Fisher Wallace Cranial Stimulator in persons with chronic migraine who have not achieved satisfactory pain control on their current medications.</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Subjects satisfying the IHS (International Headache Society) criteria for migraine Subjects have not achieved satisfactory pain control on their current medication Ability to maintain a daily headache diary Stable medication use related to migraine for at least 4 weeks prior to enrollment in the study Previous exposure to or experience with cranial electrotherapy stimulation (CES) Contraindications to Fisher Wallace stimulator, such as cardiac pacemakers or implantable defibrillators, known or suspected heart disease, or pregnancy Seizure disorders</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>